Monoclonal antibody treatment will be available to patients aged over 50 years hospitalised with COVID-19

摘要

Adults aged over 50 years, and people aged 12–49 years who are immunocompromised, will be among those eligible to receive the newly approved monoclonal antibody (MAb) cocktail, Ronapreve (casirivimab and imdevimab; Roche Products Ltd), and could do so from this week, the Department of Health and Social Care (DHSC) has said. The eligibility criteria for the treatment-which was approved in August 2021-were published in a joint interim clinical commissioning policy statement on 17 September 2021 (https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103175) by the DHSC, the Scottish government and the Welsh government.